Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Evaluation of Rhubarb Supplementation in Stages 3 and 4 of ChronicKidneyDisease: A Randomized Clinical Trial. Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronickidneydisease. Material and Methods. This study was a prospective comparative study conducted in patients of chronickidneydisease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two (...) management in stage 3 and stage 4 patients of chronickidneydisease.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronickidneydisease (the C-SURFER study): a combination phase 3 study. Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronickidneydisease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronickidneydisease have few treatment options. This study assesses an all-oral, ribavirin-free regimen (...) in patients with HCV genotype 1 infection and stage 4-5 chronickidney disease.In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronickidneydisease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done
2015LancetControlled trial quality: predicted high
A Positive Association Between Periodontal Disease and ChronicKidneyDisease is Evident, But Periodontal Treatment Effects Unknown UTCAT2938, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Positive Association Between Periodontal Disease and ChronicKidneyDisease is Evident, But Periodontal Treatment Effects Unknown Clinical Question In patients with chronickidneydisease, does periodontal treatment improve (...) kidney function (estimated glomerular filtration rate (eGFR))? Clinical Bottom Line Periodontal disease and chronickidneydisease share similar risk factors (smoking, impaired wound healing, diabetes mellitus, malnutrition, and poor oral hygiene) and a positive association between the two diseases has been shown. Intervention studies offer limited and inconsistent evidence for improvement following periodontal treatment in patients with CKD and periodontitis. No adverse outcomes were seen
with a hospital referral 21 Patient involvement in CKD 21 Appendices Appendix 1 - Where can I get more information? 22 Appendix 2 - Contact Details 23 Appendix 3 - Management of chronickidneydisease: summary table 24 Appendix 4 - Abbreviations 25 Appendix 5 - Membership of GDG 26 3 Introduction Chronickidneydisease (CKD) is common, usually unrecognised and often exists in association with other conditions such as diabetes and cardiovascular disease. CKD is a general term covering a number of primary (...) risk of cardiovascular events, acute kidney injury, falls, frailty and mortality. Table 1: Prevalence of ChronicKidneyDisease Stage Description eGFR (mL/min/1.73m 2 ) Population Prevalence 1 CKD with normal GFR + other kidney damage >90 3.3% 2 Mild CKD and other kidney damage 60-89 3.0% 3a 3b Mild to Moderate CKD Moderate to Severe CKD 45-59 30-44 4.3% 4 Severe CKD 15-29 0.2% 5 Established renal failure 30mg/mmol (macro-albuminuria often dipstick proteinuria) ? GFR in healthy young adults
equation to estimate GFR is superior for predicting adverse outcomes after PCI and to examine how equation selection would impact drug-dosing recommendations.Estimated GFR (eGFR) was calculated with the Cockcroft-Gault, Modification of Diet in RenalDisease Study (MDRD), and ChronicKidneyDisease Epidemiology Collaboration (CKD-EPI) equations for 128,805 patients undergoing PCI in the state of Michigan. Agreement between patient pre-PCI eGFR estimates and resultant CKD stage classifications (...) Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With ChronicKidneyDisease Undergoing Percutaneous Coronary Interventions Multiple equations exist to estimate glomerular filtration rate (GFR); however, there is no consensus on which is superior for risk classification in patients with chronickidneydisease (CKD) undergoing percutaneous coronary intervention (PCI).The goals of this study were to identify which
Chronickidneydisease. This issue provides a clinical overview of chronickidneydisease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration
. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Erythropoiesis Stimulating Agents in ChronicKidneyDisease (...) of vascular access thrombosis and stroke. No impacts of higher Hb targets were observed on end-stage renaldisease or all-cause mortality. 2 The identified randomized controlled trial 3 examined the effects of maintaining high Hb on renal function in patients with CKD who were not on dialysis. Patients were randomized to either a Erythropoiesis Stimulating Agents in ChronicKidneyDisease 3 high Hb group (Hb equal to 11.0 g/dL through 13.0 g/dL) receiving darbepoetin alfa or a low Hb group (Hb equal
, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dialysis in Stage 5 ChronicKidneyDisease: Clinical Effectiveness and Guidelines DATE (...) estimated GFRs was statistically significantly associated with increased risk of mortality; however, significant study heterogeneity was also noted. Dialysis in Stage 5 ChronicKidneyDisease 3 REFERENCES SUMMARIZED Health Technology Assessments No literature identified Systematic Reviews and Meta-analyses 1. O'Connor NR, Kumar P. Conservative management of end-stage renaldisease without dialysis: a systematic review. J Palliat Med [Internet]. 2012 Feb [cited 2015 Mar 13];15(2):228-35. Available from
Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, ChronicKidneyDisease, or Heart Failure Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) -Inflammatory Drugs in Patients with Hypertension, ChronicKidneyDisease, or Heart Failure: Benefits, Harms, and Guidelines DATE: 10 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of using non-steroidal anti-inflammatory drugs (NSAIDS) in patients with hypertension, chronickidneydisease, or heart failure? 2. What are the evidence-based guidelines for using NSAIDS in patients with hypertension, chronickidneydisease, or heart failure? KEY FINDINGS One systematic review, one
Hyperphosphataemia in adults with chronickidneydisease on dialysis: sucroferric oxyhydroxide Key points from the evidence | Hyperphosphataemia in adults with chronickidneydisease on dialysis: sucroferric oxyhydroxide | Advice | NICE Hyperphosphataemia in adults with chronickidneydisease on dialysis: sucroferric oxyhydroxide Evidence summary [ESNM51] Published date: January 2015 Share Save Advice Key points from the evidence Key points from the evidence The content of this evidence summary (...) was up-to-date in January 2015 . See (SPCs), (BNF) or the or websites for up-to-date information. Summary Sucroferric oxyhydroxide (Velphoro) is an iron‑based phosphate binder. In 1 open‑label, randomised controlled trial (RCT), sucroferric oxyhydroxide at a mean dose of 1500 mg iron (3 tablets) per day was non‑inferior to sevelamer carbonate at a mean dose of 6.4 g (8 tablets) per day for lowering phosphate levels in adults with chronickidneydisease (CKD) who were on haemodialysis or peritoneal
-stage kidneydisease may be suitable for laparoscopic nephrectomy. IMPLEMENTATION AND AUDIT Assessment of chronicrenal pain in patients with ADPKD attending renal clinics. A quality-of-life survey asking patients with ADPKD about pain control. Use of magnetic resonance imaging to determine whether pain is due to cyst bleeding, infection or enlargement, or to mechanical back pain. BACKGROUND Pain is very common in ADPKD, occurring in up to 60% of patients at some time. 2,3 Renal pain is found (...) group. WHAT DO THE OTHER GUIDELINES SAY? KidneyDisease Outcomes Quality Initiative: No recommendation. UK Renal Association: No recommendation. CanadianSocietyofNephrology:Norecommendation. European Best Practice Guidelines: No recommen- dation. International Guidelines: No recommendation Spanish Guidelines 28 : The cause of chronic pain should be evaluated and corrected if possible. a) Mechanicalbackpainorpainduetorenalenlarge- ment should be managed symptomatically (D). b) Narcotic analgesics
not reported in this analysis ACS indicates acute coronary syndrome; ACSIS, Acute Coronary Syndromes Israeli Survey; CI, confidence interval; CKD, chronickidneydisease; CrCl, creatinine clearance; CRI, chronicrenal insufficiency; ESRD, end-stage renaldisease; GFR, glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio; ICH, intracranial hemorrhage; ICONS, Improved Cardiac Outcomes in Nova Scotia; LBBB, left bundle branch block; OR, odds ratio; PCI, percutaneous (...) rate formula for classification of chronickidney dis- ease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991–996. doi: 10.1016/j.jacc.2007.11.045. 24. Wargo KA, Eiland EH 3rd, Hamm W, English TM, Phillippe HM. Comparison of the modification of diet in renaldisease and Cockcroft- Gault equations for antimicrobial dosage adjustments. Ann Pharmacother. 2006;40:1248–1253. doi: 10.1345/aph.1G635. 25. Golik MV, Lawrence KR. Comparison of dosing
Allopurinol for the treatment of chronickidneydisease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) competing interests of authors: none Published June 2014 DOI: 10.3310/hta18400 Scientific summary AllopurinolforthetreatmentofCKD Health Technology Assessment 2014; Vol. 18: No. 40 DOI: 10.3310/hta18400 NIHR Journals Library www.journalslibrary.nihr.ac.ukScientificsummary Background The term chronickidneydisease (CKD) is used to describe abnormal kidney function (or structure) and is defined according to the presence or absence of kidney damage and level of kidney function. Traditionally serum
a trial with a larger number of people with chronickidneydisease. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Allopurinols; Renal Insufficiency, Chronic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: firstname.lastname@example.org AccessionNumber (...) Allopurinol for the treatment of chronickidneydisease: a systematic review Allopurinol for the treatment of chronickidneydisease: a systematic review Allopurinol for the treatment of chronickidneydisease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been
of ChronicKidneyDisease Horizon Scan Report 0038 March 2014 Horizon Scan Report 0035 February 2014 d) Detection of acute on chronicrenal failure and acute kidney injury (AKI) Existing Technology: Blood samples sent from GP for analysis in local hospital laboratory. Results subsequently sent back to general practice typically within 24 hours. Depending on significance of result, this may or may not be communicated to the patient by letter, telephone or in person. Benefits of POC creatinine testing (...) /nicemedia/live/12069/42117/42117.pdf NICE clinical guideline 73. 6. Mathew TH, Corso O, Ludlow M, Boyle A, Cass A, Chadban SJ, Joyner B, Shephard M, Usherwood T. Screening for chronickidneydisease in Australia: a pilot study in the community and workplace. Kidney International – Supplement. 2010; (116): S9-16. 7. Morita S, Suzuki K, Masukawa A, Ueno E. Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. Japanese Journal of Radiology